HUP0402088A3 - Substituted piperazine and piperidine compounds pharmaceutical compositions containing them and their use for the preparation of a medicament for inhibiting fatty acid oxidation - Google Patents
Substituted piperazine and piperidine compounds pharmaceutical compositions containing them and their use for the preparation of a medicament for inhibiting fatty acid oxidationInfo
- Publication number
- HUP0402088A3 HUP0402088A3 HU0402088A HUP0402088A HUP0402088A3 HU P0402088 A3 HUP0402088 A3 HU P0402088A3 HU 0402088 A HU0402088 A HU 0402088A HU P0402088 A HUP0402088 A HU P0402088A HU P0402088 A3 HUP0402088 A3 HU P0402088A3
- Authority
- HU
- Hungary
- Prior art keywords
- medicament
- preparation
- fatty acid
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 150000004665 fatty acids Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000003647 oxidation Effects 0.000 title 1
- 238000007254 oxidation reaction Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000004885 piperazines Chemical class 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Lubricants (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Paper (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30662101P | 2001-07-19 | 2001-07-19 | |
| PCT/US2002/022897 WO2003008411A1 (en) | 2001-07-19 | 2002-07-18 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0402088A2 HUP0402088A2 (hu) | 2005-02-28 |
| HUP0402088A3 true HUP0402088A3 (en) | 2010-03-29 |
Family
ID=23186103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0402088A HUP0402088A3 (en) | 2001-07-19 | 2002-07-18 | Substituted piperazine and piperidine compounds pharmaceutical compositions containing them and their use for the preparation of a medicament for inhibiting fatty acid oxidation |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6930111B2 (enExample) |
| EP (1) | EP1406898B1 (enExample) |
| JP (1) | JP2004537554A (enExample) |
| KR (1) | KR100919141B1 (enExample) |
| CN (1) | CN1533388A (enExample) |
| AT (1) | ATE292633T1 (enExample) |
| AU (1) | AU2008202958A1 (enExample) |
| CA (1) | CA2454059A1 (enExample) |
| DE (1) | DE60203623T2 (enExample) |
| DK (1) | DK1406898T3 (enExample) |
| ES (1) | ES2236557T3 (enExample) |
| HU (1) | HUP0402088A3 (enExample) |
| IL (1) | IL159897A0 (enExample) |
| MX (1) | MXPA04000565A (enExample) |
| NO (1) | NO327635B1 (enExample) |
| NZ (1) | NZ530705A (enExample) |
| PL (1) | PL368529A1 (enExample) |
| PT (1) | PT1406898E (enExample) |
| RU (1) | RU2300533C2 (enExample) |
| WO (1) | WO2003008411A1 (enExample) |
| ZA (1) | ZA200400404B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7001909B2 (en) * | 2001-07-19 | 2006-02-21 | Cv Therapeutics, Inc. | Substituted heterocyclic compounds |
| CN100551370C (zh) * | 2002-05-21 | 2009-10-21 | Cv医药有限公司 | 雷诺嗪在制备治疗糖尿病的药物组合物中的应用 |
| US8822473B2 (en) | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| WO2004014902A2 (en) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| AR040847A1 (es) | 2002-08-09 | 2005-04-20 | Astrazeneca Ab | 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos |
| TW200424183A (en) * | 2002-08-09 | 2004-11-16 | Nps Pharma Inc | New compounds |
| EP1806346B1 (en) * | 2002-12-05 | 2009-07-22 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| ES2287574T3 (es) * | 2002-12-05 | 2007-12-16 | Cv Therapeutics, Inc. | Compuestos de piperacina sustituidos y su utilizacion como inhibidores de la oxidacion de acidos grasos. |
| KR20050086956A (ko) | 2003-01-03 | 2005-08-30 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 치환된 복소환 화합물 |
| AU2004209522A1 (en) * | 2003-01-17 | 2004-08-19 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases |
| EP1644345A1 (en) * | 2003-06-23 | 2006-04-12 | Cv Therapeutics, Inc. | Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors |
| KR20060124646A (ko) * | 2003-12-18 | 2006-12-05 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 1-아칸-2-올 치환된 피페라진 및 피페리딘 화합물 |
| EP1699527A1 (en) * | 2004-01-02 | 2006-09-13 | Advanced Cardiovascular Systems, Inc. | High-density lipoprotein coated medical devices |
| JP2008512465A (ja) * | 2004-09-08 | 2008-04-24 | シーブイ・セラピューティクス・インコーポレイテッド | 脂肪酸酸化阻害剤としての置換ピペラジン化合物およびその使用 |
| EP2056844A4 (en) | 2006-08-24 | 2010-11-24 | Wockhardt Research Center | NEW MACROLIDS AND KETOLIDS WITH ANTIMICROBIAL EFFECT |
| US8088920B2 (en) * | 2008-03-31 | 2012-01-03 | Hoffmann-La Roche Inc. | 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents |
| SMT202000257T1 (it) * | 2008-10-10 | 2020-07-08 | Vm Discovery Inc | Composizioni e metodi per il trattamento dei disturbi da uso di alcol, dolore e altre malattie |
| CA2761771A1 (en) * | 2009-05-14 | 2010-11-18 | Gilead Sciences, Inc. | Ranolazine for the treatment of cns disorders |
| JPWO2011115150A1 (ja) * | 2010-03-18 | 2013-07-04 | 興和株式会社 | ベンゾチアジン化合物の製造方法 |
| CN111285819A (zh) * | 2018-12-07 | 2020-06-16 | 江苏恩华药业股份有限公司 | 一种苯并噁唑类化合物及其应用 |
| WO2023023995A1 (zh) * | 2021-08-25 | 2023-03-02 | 苏州大学 | 一种防治心肌缺血后心功能衰竭的药物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1133989A (en) | 1964-12-08 | 1968-11-20 | Chugai Pharmaceutical Co Ltd | Theophylline derivatives, their salts and process for preparing the same |
| DE2834114A1 (de) * | 1978-08-01 | 1980-02-14 | Schering Ag | Polyalkoxyphenylpyrrolidone iii, verfahren zu ihrer herstellung und ihre verwendung |
| US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| JPS6137765A (ja) * | 1984-07-19 | 1986-02-22 | サンド・アクチエンゲゼルシヤフト | ３‐アミノプロポキシアリール誘導体 |
| US4723014A (en) * | 1986-11-19 | 1988-02-02 | Warner-Lambert Company | Process for the preparation of 2-substituted-1,4-dihydropyridines |
| DE3723648A1 (de) * | 1987-07-17 | 1989-01-26 | Sandoz Ag | Indol-derivate, ihre herstellung und sie enthaltende arzneimittel |
| JPH0699399B2 (ja) * | 1988-10-06 | 1994-12-07 | 三井東圧化学株式会社 | 新規複素環化合物およびそれを有効成分として含有する製癌剤効果増強剤 |
| JPH02268162A (ja) * | 1989-04-10 | 1990-11-01 | Fujisawa Pharmaceut Co Ltd | ジフェニルピリジン誘導体 |
| MX9308025A (es) * | 1992-12-22 | 1994-08-31 | Lilly Co Eli | Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene. |
| WO1998021190A1 (en) * | 1996-11-14 | 1998-05-22 | American Home Products Corporation | Substituted tetrahydro-1,3,5-triazin-2[1h]-thiones as anti-atherosclerotic agents |
| EP1212335B1 (en) * | 1999-09-13 | 2006-01-18 | Wyeth | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1- 4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols |
| SE9904765D0 (sv) | 1999-12-23 | 1999-12-23 | Astra Ab | Pharmaceutically-useful compounds |
| CA2400176C (en) * | 2000-02-22 | 2009-04-28 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| AU2001239827A1 (en) * | 2000-02-22 | 2001-09-03 | Cv Therapeutics, Inc. | Substituted alkylene diamine compounds |
| WO2001062749A1 (en) | 2000-02-22 | 2001-08-30 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| US6552023B2 (en) | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
| SE0003795D0 (sv) * | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Pharmaceutically useful compounds |
| US6573264B1 (en) | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
-
2002
- 2002-07-18 DK DK02756522T patent/DK1406898T3/da active
- 2002-07-18 NZ NZ530705A patent/NZ530705A/en not_active IP Right Cessation
- 2002-07-18 CN CNA02814371XA patent/CN1533388A/zh active Pending
- 2002-07-18 RU RU2004104951/04A patent/RU2300533C2/ru not_active IP Right Cessation
- 2002-07-18 MX MXPA04000565A patent/MXPA04000565A/es active IP Right Grant
- 2002-07-18 CA CA002454059A patent/CA2454059A1/en not_active Abandoned
- 2002-07-18 IL IL15989702A patent/IL159897A0/xx unknown
- 2002-07-18 AT AT02756522T patent/ATE292633T1/de not_active IP Right Cessation
- 2002-07-18 US US10/198,237 patent/US6930111B2/en not_active Expired - Fee Related
- 2002-07-18 WO PCT/US2002/022897 patent/WO2003008411A1/en not_active Ceased
- 2002-07-18 ES ES02756522T patent/ES2236557T3/es not_active Expired - Lifetime
- 2002-07-18 PT PT02756522T patent/PT1406898E/pt unknown
- 2002-07-18 HU HU0402088A patent/HUP0402088A3/hu unknown
- 2002-07-18 EP EP02756522A patent/EP1406898B1/en not_active Expired - Lifetime
- 2002-07-18 DE DE60203623T patent/DE60203623T2/de not_active Expired - Fee Related
- 2002-07-18 JP JP2003513970A patent/JP2004537554A/ja not_active Ceased
- 2002-07-18 KR KR1020047000898A patent/KR100919141B1/ko not_active Expired - Fee Related
- 2002-07-18 PL PL02368529A patent/PL368529A1/xx not_active Application Discontinuation
-
2004
- 2004-01-19 ZA ZA200400404A patent/ZA200400404B/en unknown
- 2004-01-19 NO NO20040234A patent/NO327635B1/no not_active IP Right Cessation
-
2008
- 2008-07-03 AU AU2008202958A patent/AU2008202958A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1406898B1 (en) | 2005-04-06 |
| DE60203623T2 (de) | 2006-01-19 |
| AU2008202958A1 (en) | 2008-07-31 |
| RU2004104951A (ru) | 2005-06-27 |
| CA2454059A1 (en) | 2003-01-30 |
| PT1406898E (pt) | 2005-08-31 |
| ES2236557T3 (es) | 2005-07-16 |
| HK1064374A1 (en) | 2005-01-28 |
| ATE292633T1 (de) | 2005-04-15 |
| AU2002322527A2 (en) | 2003-03-03 |
| US20030181352A1 (en) | 2003-09-25 |
| RU2300533C2 (ru) | 2007-06-10 |
| NO327635B1 (no) | 2009-09-07 |
| NO20040234L (no) | 2004-03-18 |
| US6930111B2 (en) | 2005-08-16 |
| PL368529A1 (en) | 2005-04-04 |
| DK1406898T3 (da) | 2005-05-30 |
| JP2004537554A (ja) | 2004-12-16 |
| EP1406898A1 (en) | 2004-04-14 |
| IL159897A0 (en) | 2004-06-20 |
| HUP0402088A2 (hu) | 2005-02-28 |
| CN1533388A (zh) | 2004-09-29 |
| ZA200400404B (en) | 2004-10-14 |
| WO2003008411A1 (en) | 2003-01-30 |
| NZ530705A (en) | 2005-08-26 |
| MXPA04000565A (es) | 2005-06-17 |
| KR20040029374A (ko) | 2004-04-06 |
| KR100919141B1 (ko) | 2009-09-25 |
| AU2002322527B2 (en) | 2008-04-17 |
| DE60203623D1 (de) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0302656A3 (en) | Fumaric acid amides, their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing the compounds | |
| HUP0303552A3 (en) | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors and pharmaceutical compositions containing them | |
| IL162213A0 (en) | Pharmaceutical compositions containing active vitamin d compounds | |
| HUP0204496A3 (en) | Novel piperidine compounds and pharmaceutical compositions containing the same and process for preparation the same | |
| HUP0303810A3 (en) | Carboxylic acid derivative and salt thereof and pharmaceutical compositions containing them | |
| HUP0400206A3 (en) | Imidazolidindion derivatives having metalloproteinase inhibitor effect a their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing them | |
| IL209444A0 (en) | O-desmethyl-venlafaxine succinate salts and pharmaceutical compositions containing them | |
| HUP0302319A3 (en) | Pharmaceutical composition for oral administration of active ingredient | |
| HUP0203431A3 (en) | Novel heterocyclic compounds and salts thereof and pharmaceutical compositions containing and use of the same | |
| HUP0303325A3 (en) | Pharmaceutical salts and pharmaceutical compositions containing them | |
| PL356358A1 (en) | Solid dosage form of someticone for oral administration | |
| EE200200021A (et) | Asendamatuid rasvhappeid ja homotsüsteiini taset alandavaid aineid sisaldavad farmatseutilised ühendid ja toidulisandid | |
| HUP0302358A3 (en) | Piperazinedione compounds and use of them for producing pharmaceutical compositions | |
| HUP0401333A3 (en) | Spiropyrazole compounds and pharmaceutical compositions containing them | |
| HUP0204143A3 (en) | Tricyclic 1-benzylpyrazole-3-carboxylic acid derivatives, preparation of the compounds, their use and pharmaceutical compositions containing them | |
| HUP0500017A3 (en) | Alkyl ether derivatives or salts thereof and pharmaceutical compositions containing them | |
| HUP0204458A3 (en) | Derivatives of quinoline as alpha-2 antagonists and pharmaceutical compositions containing them | |
| HUP0203311A3 (en) | New pharmaceutical compositions of prolonged effect | |
| IL161430A0 (en) | Pharmaceutical compositions containing ecteinascidin 743 | |
| HUP0401747A3 (en) | Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds | |
| IL151369A (en) | Use of tgf-beta antagonist for the preparation of pharmaceuticals | |
| HUP0400386A3 (en) | Tablet comprising cetirizine and pseudoephedrine and its use for preparation of pharmaceutical compositions | |
| IL161348A (en) | Substituted 4- phenyl-4-[1h - imidazol-2-yl] piperidine derivatives and their use for the preparation of pharmaceutical compositions | |
| HUP0303636A3 (en) | Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient | |
| IL158863A0 (en) | A crystalline co-precipitate of gatifloxacin and a fatty acid and pharmaceutical compositions containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |